Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.5%. By the end of trading, Regeneron Pharmaceuticals fell $3.72 (-2.3%) to $155.28 on light volume. Throughout the day, 438,700 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 721,300 shares. The stock ranged in price between $154.65-$159.62 after having opened the day at $158.76 as compared to the previous trading day's close of $159. Other companies within the Health Care sector that declined today were: Telik ( TELK), down 15.3%, Theratechnologies ( THER), down 15.1%, Hemispherx Biopharma ( HEB), down 11%, and Oxygen Biotherapeutics ( OXBT), down 8.7%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $15.15 billion and is part of the drugs industry. Shares are up 191% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, compelling growth in net income, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Fonar Corporation ( FONR), up 13.1%, Cleveland BioLabs ( CBLI), up 12.3%, Delcath Systems ( DCTH), up 11.6%, and Vivus ( VVUS), up 10.2%, were all gainers within the health care sector with Questcor Pharmaceuticals ( QCOR) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round